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Summary Early right ventricular dysfunction after heart transplantation (HTx) is a major com-
plication especially in patients with pre-transplant pulmonary arterial hypertension (PH). The
possibility to reverse secondary PH using sodium nitroprusside (NPS) or inhaled nitric oxide has
been already established and there is a well-known stratification of the incidence of early death
after HTx related to the reversibility of PH. Despite this, in a group of patients with irreversible
disorders of the pulmonary vascular bed, conventional therapy may not be useful. However, the
decision to disqualify non-responsive HTx candidates may be inappropriate, considering that
PH unresponsiveness to NPS does not exclude the possibility to decrease pulmonary pressures
with other medications. In case of non-responsive patients, the debate regarding the role of
new selective pulmonary vasodilators is still open and oral sildenafil use in cardiac transplant
candidates and recipients is growing. Despite this, there are many reports of the use of phos-
phodiesterase 5 inhibitors in patients with chronic heart failure and several studies describe the
positive effects of sildenafil in reducing pulmonary vascular resistance and pulmonary arterial
pressure and in increasing cardiac output. Oral sildenafil use in cardiac transplant candidates
or recipients is still limited.
© 2010 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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ntroduction
n chronic heart failure, the elevated left ventricular
nd-diastolic pressure may lead to pulmonary arterial
ypertension (PH) either by indirect ‘‘reactive’’ pulmonary
asoconstriction or by retrograde direct transmission of the
ncreased pressure to the lungs. PH is present when mean
ulmonary artery pressure (mPAP) is greater than 25mmHg
t rest or greater than 30mmHg with exercise [1]. It is
haracterized by complex vascular changes with the final
esult of an increased PAP and pulmonary vascular resistance
PVR). This modification is initially reversible but progres-
ively collagen deposition in the pulmonary arteries leads
o irreversible structural changes. At this stage PH and PVR
ecome non-reactive to common pulmonary vasodilators.
The ‘‘milestone’’ in the treatment of PH is inhaled nitric
xide (iNO) that causes pulmonary vasodilatation increas-
ng cyclic guanyl monophosphate (cGMP) levels in pulmonary
essels. iNO is inactivated directly in the lumen of the vessel
imiting its effect to the vascular smooth muscle adjacent
o the alveolar unit. Although iNO is the most effective and
elective pulmonary vasodilator, its use is limited because of
he complicated delivery system that requires mechanical
entilation, the high costs of the medical form of NO gas,
he necessity of invasive monitoring system, and the very
hort half-life. Despite these limitations, iNO is considered
he gold standard in pre-transplant evaluation of patients
ith PH [2,3] and some authors [4] suggested the use of
NO immediately after heart transplantation to prevent early
ight ventricular dysfunction (RVD). Moreover, iNO is the only
elective pulmonary vasodilator that does not require the
se of a vasoconstrictor to support systemic blood pressure.
owever, the debate regarding the role of new selective pul-
onary vasodilators is still open [5,6] and oral sildenafil use
n cardiac transplant candidates and recipients is growing
p [7—11].
Many other drugs have been used for the treatment of PH
uch as:
Isoproterenol: nonselective  receptor agonist that
induces pulmonary and systemic vasodilatation increas-
ing cardiac output (CO). Its short half-life should induce
acute increase of PVR after therapy discontinuation with
bad prognosis.
Dobutamine: selective 2 receptors agonist with vasodila-
tor effect, ideal in case of heart failure associated with
high PVR. It should increase myocardial oxygen demand.
Phosphodiesterase III inhibitors (milrinone): inotropic
drug with a vascular smooth muscle-relaxing effect
mediated by cyclic adenosine monophosphate pathway.
It should be used in association with 2 receptors
(dobutamine) because of their different but synergistic
mechanisms of action.
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Prostaglandin E1 and prostacyclin: they are potent
pulmonary vasodilators unfortunately with significant sys-
temic effects. They have very short half-lives due to quick
degradation in lungs and liver.
n addition to using these drugs, some authors believe that
he use of oversized donor in case of preoperative PH should
mprove the adaptation of the organ implanted to high PAP
12], but other investigators [13] demonstrated that the out-
ome of recipients was not related to the heart size.
However, the recent introduction of new selective pul-
onary vasodilators added new resources in the treatment
f PH: many reports suggested that non-responders to
odium nitroprusside (NPS) or iNO tests, should be favored
y the use of other vasodilators as inhaled or intravenous
loprost, endothelin receptor inhibitors [2,3], and in recent
ears by phosphodiesterase 5 inhibitors (PDE-5i).
ildenafil and pulmonary arterial hypertension
he effects of sildenafil on pulmonary vessels were inves-
igated during recent years when initial reports describing
emodynamic results with PDE-5i were presented. Pul-
onary vasodilatation is caused by the increased levels of
GMP in vascular smooth muscle cells [14]. cGMP has a short
ife because of its degradation by phosphodiesterase 5 (PDE-
), which is the active iso-form in the lung [15]. All the
rocesses able to enhance the effects of PDE-5 or reduce
GMP levels, like hypoxia, may cause pulmonary vasocon-
triction and then PH.
On this basis, the possibility of using PDE-5i to induce
ulmonary vasodilatation (enhancing the levels of intracel-
ular cGMP) was considered and a drug everywhere used for
rectile dysfunction [16] was investigated for its activity on
VR in patients with PH [17,18] or in case of hypoxia-related
ulmonary vasoconstriction [19].
Supported by these preliminary data and considering the
imilar mechanism of action of PDE-5i and iNO, Michelakis
t al. [20] reported their initial experience with oral silde-
afil in patients evaluated for heart and lung transplantation
nd compared the data on sildenafil therapy with those
btained with iNO. This paper was the first evidence of
he effects of PDE-5i on pulmonary circulation: a single
ose of oral sildenafil (75mg) is a potent and selective pul-
onary vasodilator compared with iNO (80 ppm). Sildenafil
s superior in decreasing the mPAP and equally effective
nd selective in reducing PVR and it causes a significant
ncrease in cardiac index. Sildenafil resulted in a higher
eduction of pulmonary artery wedge pressure (PAWP) than
NO and this has positive effects on the patients’ symptoms
ith end-stage heart failure and it may prevent pulmonary
dema (rare complication during iNO therapy). In that paper
he effects of oral sildenafil and iNO were at least compa-
able: furthermore, their actions are synergistic and this
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is a new opportunity in the treatment of low-responsive
patients.
The effects of sildenafil in patients both with idiopathic
PH and with secondary PH were investigated by Ghofrani et
al. [21]. They reported that 120 or 180min after low/or high
doses of oral sildenafil (12.5 or 50mg) alone or in combina-
tion with inhaled iloprost, there was a significant decrease in
PVR and PAPs with increase of CO and improvement in symp-
toms. This report confirmed the additive effects of PDE-5i
with inhaled iloprost. Another study by Ghofrani et al. [22]
confirmed the data reported above in patients with lung
fibrosis.
Sildenafil and heart transplantation
Sildenafil use in heart transplantation (HTx) started about
5 years after the first use of sildenafil in non-transplant
patients with PH. The major limitation of its use in HTx
was related to the possible interferences with immunosup-
pressive drugs and the possibility of negative effects on
the implanted organ. Considering that PVR from 3 to 5
Wood units and transpulmonary gradients >15mmHg have
accounted for a 3—5-fold increased risk of mortality within
the initial 30 days after heart transplantation [23] and many
vasodilators as iNO, prostacyclin, nitroglycerine, and NPS
have been used with varying success to treat RVD due to PH
[24], many authors started to be interested in the use of
oral sildenafil in heart transplant candidates or recipients
with PH because of its easiness of administration, its low
cost, its safety, and its additive effects with all the other
vasodilators.
Acute RVD remains a difficult and ever-present clinical
syndrome in the transplant recipient. Avoidance of RVD after
HTx is unfortunately, not possible. Goals in the treatment of
this clinical problem include: coronary perfusion maintain-
ing high systemic blood pressure, reducing RV preload with
diuretics and RV afterload by decreasing PVR, avoidance of
pulmonary vasoconstriction using high inspired oxygen con-
centrations and increased tidal volume.
In the last few years, the effects of oral sildenafil in heart
transplant patients started to be investigated and many
authors reported their preliminary experience.
An interesting study published in 2003 [25] described the
use of 50mg of sildenafil in heart transplant recipients with
erectile dysfunction: the authors concluded that sildenafil is
well tolerated in these patients avoiding hypotension and by
decreasing the amplitude of the reflected pressure wave and
delaying its return to the heart, sildenafil reduces left ven-
tricular afterload and systolic stress. Moreover, some other
authors suggested that the use of sildenafil in hypertensive
transplanted patients should have a synergistic role in reduc-
tion of systemic blood pressure, improving heart function
[26].
Many authors focused their attention on the role of
sildenafil in pre-transplant candidates. An interesting paper
published in 2007 described the experience with six patients
with PH awaiting HTx: in five of these patients PH was
reversed and they were enrolled on the waiting list for HTx.
Despite this, the major limit of this study is that the patients
described were not yet transplanted and this does not allow
evaluating the role of pre-transplant therapy with sildenafil
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n the overall mortality after heart transplantation. The
uthors concluded that sildenafil can be effectively used
o treat secondary irreversible PH among potential heart
ransplant candidates, allowing qualification for HTx [10].
Moreover, some authors use oral sildenafil as a vasodila-
or drug for preoperative evaluation in patients with PAH.
hey reported that sublingual sildenafil causes a rapid and
elective decrease in mean transpulmonary gradient, mPAP,
nd PVR in HTx patients with PH due to left ventricular
ystolic dysfunction, without significant changes in mean
ulmonary wedge pressure, CO, and systemic vascular resis-
ance. They concluded that sublingual sildenafil is a simple
cute vasodilator test in heart transplant candidates with
H [27].
In 2004, the first report of Kulkarni et al. [11] described
he use of oral sildenafil in a young transplant recipient
ith post-transplant PH complicated by RVD and tricuspid
egurgitation: oral sildenafil (0.5mg/kg every 4 h), added
o inotropes and vasodilators (milrinone and nitroglycerine)
n 2nd postoperative day, enabled quick decrease in PAP,
AWP, PVR, and central venous pressure and a fast improve-
ent in urine output allowing a fast weaning of intravenous
notropes and vasodilators.
In 1971, Griepp et al. [28] first reported the relationship
etween elevated preoperative PVR and the risk of death
rom acute RVD after heart transplantation. Numerous other
tudies confirmed this association [29—31].
ersonal experience
e have analyzed the data obtained from patients with RVD
fter heart transplantation [32]: in our experience about
0—15% of all transplant recipients suffered for RVD at
ifferent time after transplantation. We treated patients
uffering from RVD after HTx with conventional therapy
ncluding inotropes, iNO, and intravenous NPS: they received
ral sildenafil in the postoperative period in order to stop the
nhaled and intravenous drugs administration. RVD diagnosis
as assessed by:
direct inspection during cardiopulmonary by-pass wean-
ing with the evidence of right ventricular dysfunction and
dilatation;
transesophageal echocardiography with the evidence of
right ventricular hypokynesia and dysfunction;
hemodynamic parameters measured using Swan Ganz
catheter;
clinical evaluation such as signs of good peripheral perfu-
sion, diuresis, hepatic and pulmonary function.
In order to offer the possibility of weaning from intra-
enous or inhaled drugs administration, we added oral
ildenafil during intensive care unit (ICU) stay: the principal
im of this approach was to reduce time of intubation and
CU stay. Early hemodynamic data (during conventional ther-
py alone) were compared with late hemodynamic results
oral sildenafil therapy alone). The main result of our analy-
is was the evidence of a significant reduction in PAP values
fter inotropes weaning and introduction of oral sildenafil.
owever, it is not possible to demonstrate that the hemody-
amic improvement is completely related to oral sildenafil
2c
t
a
o
s
t
D
R
s
i
a
s
a
p
p
o
s
s
t
m
d
a
d
a
t
t
i
l
s
t
d
e
h
P
o
l
s
t
s
a
t
r
a
v
p
s
f
P
e
v
a
s
l
o
t
w
i
p
C
O
e
a
I
a
a
R
[
[
[
[94
onsidering that the physiologic hemodynamic resetting of
he new heart in the recipient should play a role. Our results,
lthough in a limited number of patients, show the efficacy
f sildenafil in reducing PAP and increasing CO in patients
uffering from RVD after HTx and suggest that oral adminis-
ration of sildenafil may be safe and feasible.
iscussion
ight ventricular function immediately after HTx is the
trong determinant of heart transplant recipient outcome:
n fact, RVD is caused by different causes and it has a neg-
tive impact on heart transplant recipient survival. Many
trategies have been proposed to prevent and to treat RVD
fter HTx such as the use of drugs like isoproterenol, NPS,
rostaglandin E1, prostacyclin, or the use of mechanical sup-
ort of right ventricular function. From one side, the use
f these drugs induces pulmonary vasodilatation, but the
ide effect of systemic hypotension should be always con-
idered. Many efforts have been focused in order to develop
he ideal pulmonary vasodilator. At the moment, NO is the
ost effective and selective pulmonary vasodilator: it is pro-
uced in the lung by NO synthase and it is a powerful, rapidly
cting, and selective pulmonary vasodilator. iNO selectively
ilates pulmonary vessels, decreasing PVR and PAP without
ffecting systemic vascular resistance. The major limita-
ion of its application is the complicated delivery system
hat requires mechanical ventilation and needs orotracheal
ntubation.
Sildenafil is an oral inhibitor of PDE-5. Pulmonary vasodi-
ation is caused by increase of the levels of cGMP in vascular
mooth muscle cells [14]. cGMP has a short life because of
he degradation by PDE-5, which is the active iso-form in
egrading cGMP in the lung [15]. All the processes able to
nhance the effects of PDE-5 or reduce cGMP levels, like
ypoxia, may cause pulmonary vasoconstriction and then
H. PDE-5 is the pulmonary iso-form of PDE-5i and inhibition
f PDE-5 by sildenafil leads to a selective pulmonary vasodi-
atation with minimal systemic side effects. The use of oral
ildenafil after HTx has not been well established because of
he suspect of drug interaction between PDE-5i and immuno-
uppressive drugs: sildenafil in the postoperative period
fter HTx as treatment of RVD may be quite common in cen-
ers performing HTx, but its use has not yet been clearly
ecommended. In our experience the use of oral sildenafil
llowed a gradual weaning from inotropic and pulmonary
asodilator drugs, iNO and mechanical ventilation in all
atients suffering from RVD after HTx. This strategy presents
everal advantages. First a shorter need for iNO allows a
aster weaning of the patients from mechanical ventilation.
DE-5i facilitates gas exchange and improves ventilation
fficiency because they preferentially dilate vessels in well-
entilated areas of the lung reducing vascular resistance
nd improving overall oxygenation (‘‘re-matching’’ drug). A
horter ventilation time may lead to a reduced risk of venti-
ator associated pulmonitis. Considering the known effect
f sildenafil on PH and the relation between the reduc-
ion in PAP and the improvement in right ventricular stroke
ork, this drug may allow right ventricular recovery. Another
mportant aspect is the relative low cost of sildenafil if com-
ared with other therapies for PH.
[F. Sansone, M. Rinaldi
onclusion
n the basis of the data reported in literature and our
xperience we can affirm that oral sildenafil represents
n attractive alternative in the treatment of PH and RVD.
ts low cost and oral administration are two important
dvantages in comparison with other therapies nowadays
vailable.
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